NOTV Share Price Performance
US$0.81
-3.11 (-79.40%)
91.0% undervalued intrinsic discount
US$9.00
Fair Value
Price US$0.81
AnalystHighTarget US$9.00
AnalystLowTarget US$2.50
AnalystConsensusTarget US$4.83
Fair ValueUS$9.00
Share Pricen/a
Inotiv, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
NOTV Community Narratives
AN
Fair Value US$9 91.0% undervalued intrinsic discount
Secular Demand For Novel Pharmaceuticals Will Expand Preclinical Services
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$2.5 67.7% undervalued intrinsic discount
Debt And Shifting Regulations Will Strain Performance But Prompt Recovery
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$4.83 83.3% undervalued intrinsic discount
Global Pharma And Biotech R&D Increase Will Build Value
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
Global Pharma And Biotech R&D Increase Will Build Value
Key Takeaways Growth in global R&D spending and greater outsourcing by biopharma are fueling rising demand for Inotiv's expanded preclinical CRO services and recurring business. Operational efficiencies, strategic acquisitions, and focus on animal welfare and accreditation are driving margin stability, premium pricing, and long-term earnings growth.Read more
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
US$4.83
83.3% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
5.22% p.a.
Profit Margin
15.51%
Future PE
2.6x
Price in 2028
US$6.72
Debt And Shifting Regulations Will Strain Performance But Prompt Recovery
Key Takeaways Shifting industry practices, high fixed costs, and integration risks threaten margin expansion and create uncertainty in revenue predictability and backlog conversion. Evolving alternatives to animal testing, rising debt costs, and client trends could undermine traditional revenue streams and weigh on future growth opportunities.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$2.5
67.7% undervalued intrinsic discount
AnalystLowTarget Fair Value
Revenue
5.03% p.a.
Profit Margin
14.2%
Future PE
1.79x
Price in 2028
US$1.97
Secular Demand For Novel Pharmaceuticals Will Expand Preclinical Services
Key Takeaways Deep integration, digital investments, and acquisition consolidation position Inotiv for sustained margin expansion, significant operating leverage, and stronger long-term earnings power than consensus suggests. Accelerating bookings, pharmaceutical outsourcing trends, and robust client satisfaction drive market share gains, premium pricing power, and enduring multi-year revenue growth.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$9
91.0% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue
5.42% p.a.
Profit Margin
14.18%
Future PE
6.38x
Price in 2028
US$7.1
Trending Discussion
Recently Updated Narratives
AN
NOTV: Future Margins And Legal Settlement Will Support Share Upside
Fair Value: US$4.83 83.3% undervalued intrinsic discount
5 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Debt And Shifting Regulations Will Strain Performance But Prompt Recovery
Fair Value: US$2.5 67.7% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Secular Demand For Novel Pharmaceuticals Will Expand Preclinical Services
Fair Value: US$9 91.0% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Inotiv, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -2.00
- 23.58%
- -13.38%
- 291.5%
About NOTV
- Founded
- 1974
- Employees
- 2026
- CEO
- WebsiteView website
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the company’s BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.
